Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF-187)

Citation
Gf. Samelis et al., Doxorubicin cardiotoxicity and serum lipid increase is prevented by dextrazoxane (ICRF-187), ANTICANC R, 18(5A), 1998, pp. 3305-3309
Citations number
28
Categorie Soggetti
Onconogenesis & Cancer Research
Journal title
ANTICANCER RESEARCH
ISSN journal
02507005 → ACNP
Volume
18
Issue
5A
Year of publication
1998
Pages
3305 - 3309
Database
ISI
SICI code
0250-7005(199809/10)18:5A<3305:DCASLI>2.0.ZU;2-M
Abstract
This study is related to the serious side effects of Doxorubicin-cardiotoxi city and serum lipid caused by the drug's cumulative effect. Studies were p erformed on experimental animals treated with intensive administration of D oxorubicin. Seventy five wistar rats were divided in two equal groups A and B. Group A was used for doxorubicin administration and B for doxorubicin a nd dextrazoxane. The drugs were administered weekly for twelve weeks at dos es 0.2mg/100g BW for doxorubicin and 1,5 mg/100g BW for dextrazoxane. Histo logical examination of the cardiac muscle, large vessels, liver and other o rgans and biochemical examination for serum lipids and liver enzymes were p erformed on certain weeks. Comparison of the findings of the two groups sho wed a) a reduction in doxorubicin cardiotoxicity by dextrazoxane and b) the addition of dextrazoxane to doxorubicin resulted in lowering the increase of serum lipids produced by doxorubicin, c) In vitro tests by chemiluminesc ence showed that dextrazoxane acts as scavenger of oxygen free radicals.